{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:23:08Z","timestamp":1780471388564,"version":"3.54.1"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Juvenile localized scleroderma (jLS) is a chronic autoimmune and fibrosing disease associated with a high risk for functional impairment. Antifibrotic options are limited, so current treatment strategies are focused on disease activity control. Pediatric rheumatologists are in consensus on the need to treat with systemic immunosuppressants, in particular, methotrexate. However, more than 30% of patients fail initial methotrexate treatment. This review provides an update on current management and reviews reports on potential alternative treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>An overview of current treatment recommendations and its efficacy are discussed. Recent studies have identified several factors associated with likelihood of treatment response. These include time to initiation of treatment, certain subtypes, and extracutaneous involvement. Findings from recent reports of alternative systemic immunomodulators, including biologic medications, will be summarized.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Methotrexate treatment has greatly improved outcome for most jLS patients but a substantial portion have refractory cutaneous and\/or extracutaneous disease. Treatment response factors are being identified, which could lead to improved management strategies. Recent studies provide further support on mycophenolate mofetil as an alternative treatment. Data on biologic therapies is encouraging, with data suggesting efficacy for many extracutaneous manifestations but more studies are needed to evaluate these and other options for jLS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000886","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T11:00:06Z","timestamp":1658833206000},"page":"245-254","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of juvenile localized scleroderma: current recommendations, response factors, and potential alternative treatments"],"prefix":"10.1097","volume":"34","author":[{"given":"Suzanne C.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3389\/fimmu.2019.00908","article-title":"Immunopathogenesis of pediatric localized scleroderma","volume":"10","author":"Torok","year":"2019","journal-title":"Front Immunol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.rdc.2021.07.014","article-title":"Juvenile localized scleroderma: updates and differences from adult-onset disease","volume":"47","author":"Vasquez-Canizares","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1093\/rheumatology\/keab238","article-title":"Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"245.e2","DOI":"10.1016\/j.jpeds.2021.01.068","article-title":"Morbidity and disability in juvenile localized scleroderma: the case for early recognition and systemic immunosuppressive treatment","volume":"234","author":"Li","year":"2021","journal-title":"J Pediatr"},{"key":"R5-20250526","first-page":"CD005027","article-title":"Interventions for morphea","volume":"7","author":"Albuquerque","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2018-214697","article-title":"Consensus-based recommendations for the management of juvenile localised scleroderma","volume":"78","author":"Zulian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/acr.21687","article-title":"Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma","volume":"64","author":"Li","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.30264","article-title":"Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Zulian","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3899\/jrheum.190311","article-title":"Initial results from a pilot comparative effectiveness study of 3 methotrexate-based consensus treatment plans for juvenile localized scleroderma","volume":"47","author":"Li","year":"2020","journal-title":"J Rheumatol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00296-019-04269-w","article-title":"Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review","volume":"39","author":"Soh","year":"2019","journal-title":"Rheumatol Int"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2340\/00015555-2411","article-title":"Drug survival and predictors of drug survival for methotrexate treatment in a retrospective cohort of adult patients with localized scleroderma","volume":"96","author":"Mertens","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"R12-20250526","first-page":"171","article-title":"Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases","volume":"13","author":"Marzano","year":"2003","journal-title":"Eur J Dermatol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjd.13514","article-title":"Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease","volume":"172","author":"Mertens","year":"2015","journal-title":"Br J Dermatol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.autrev.2018.02.004","article-title":"Disease course and long-term outcome of juvenile localized scleroderma: experience from a single pediatric rheumatology Centre and literature review","volume":"17","author":"Martini","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/acr.24260","article-title":"Methotrexate in linear scleroderma: long-term efficacy in fifty children from a single pediatric rheumatology center","volume":"73","author":"Fadanelli","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jaad.2012.03.036","article-title":"A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea)","volume":"67","author":"Zulian","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"567","DOI":"10.5152\/eurjrheum.2019.19147","article-title":"Characteristics of coexisting localized scleroderma and inflammatory arthritis","volume":"7","author":"Reiff","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"e20161899","DOI":"10.1542\/peds.2016-1899","article-title":"Fibrous arthropathy associated with morphea: a new cause of diffuse acquired joint contractures","volume":"140","author":"Merlin","year":"2017","journal-title":"Pediatrics"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"47.e2","DOI":"10.1016\/j.jaad.2018.03.005","article-title":"Inflammatory arthritis in pediatric patients with morphea","volume":"79","author":"Kashem","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s10067-019-04850-5","article-title":"Association of juvenile idiopathic arthritis and morphea: a case series","volume":"39","author":"Giani","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1546-0096-12-27","article-title":"A cross-sectional electromyography assessment in linear scleroderma patients","volume":"12","author":"Saad Magalh\u00e3es","year":"2014","journal-title":"Pediatric Rheumatology"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1111\/pde.12799","article-title":"Radiologic improvement after early medical intervention in localised facial morphea","volume":"33","author":"Khan","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"e1715","DOI":"10.1542\/peds.2014-0019","article-title":"Headaches as a presenting symptom of linear morphea en coup de sabre","volume":"134","author":"Polcari","year":"2014","journal-title":"Pediatrics"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"101457","DOI":"10.1016\/j.msard.2019.101457","article-title":"Extensive linear scleroderma en coup de sabre with exertion-induced hemiplegic migraine","volume":"37","author":"Martins","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1212\/01.wnl.0000334474.88923.e3","article-title":"Neurologic manifestations of localized scleroderma: a case report and literature review","volume":"71","author":"Kister","year":"2008","journal-title":"Neurology"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-019-1015-7","article-title":"Linear scleroderma \u2018en coup de sabre\u2019 with extensive brain involvement \u2014 clinicopathologic correlations and response to anti-Interleukin-6 therapy","volume":"14","author":"Magro","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.reuma.2018.05.001","article-title":"Scleroderma \u2018en coup de sabre\u2019 with epilepsy and uveitis successfully treated with tocilizumab","volume":"16","author":"Osminina","year":"2020","journal-title":"Reumatol Clin"},{"issue":"(Suppl 4)","key":"R28-20250526","first-page":"137","article-title":"Reliability and validity of a new skin activity measure for localized scleroderma [abstract]. Pediatric Rheumatology Symposium of American College of Rheumatology [virtual]","volume":"72","author":"Li","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/jdv.16308","article-title":"Prospective evaluation of treatment response and disease reversibility of paediatric localized scleroderma (morphoea) to steroids and methotrexate using multimodal imaging","volume":"34","author":"Weibel","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/rheumatology\/keaa392","article-title":"Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma","volume":"60","author":"Martini","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jid.2018.01.006","article-title":"Mycophenolate mofetil treatment of systemic sclerosis reduces myeloid cell numbers and attenuates the inflammatory gene signature in skin","volume":"138","author":"Hinchcliff","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"Milano","year":"2008","journal-title":"PLoS One"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2020.0035","article-title":"Evaluation of the effectiveness and tolerability of mycophenolate mofetil and mycophenolic acid for the treatment of morphea","volume":"156","author":"Arthur","year":"2020","journal-title":"JAMA Dermatol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/1346-8138.14801","article-title":"Juvenile case of multiple morphea profunda resulting in joint contracture that was successfully treated with cyclosporin A: a case report and review of the published works","volume":"46","author":"Ogawa","year":"2019","journal-title":"J Dermatol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000448171","article-title":"Cyclosporine reduces sclerosis in morphea: a retrospective study in 12 patients and a literature review","volume":"232","author":"Bali","year":"2016","journal-title":"Dermatology"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.jaad.2019.01.040","article-title":"Treatment of morphea with hydroxychloroquine: a retrospective review of 84 patients at Mayo Clinic, 1996\u20132013","volume":"80","author":"Kumar","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"1446.e4","DOI":"10.1016\/j.jid.2019.12.019","article-title":"Jak inhibition prevents bleomycin-induced fibrosis in mice and is effective in patients with morphea","volume":"140","author":"Damsky","year":"2020","journal-title":"J Invest Dermatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archdermatol.2010.120","article-title":"Treatment of recalcitrant generalized morphea with infliximab","volume":"146","author":"Diab","year":"2010","journal-title":"Arch Dermatol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/18743129014090100030","article-title":"A case report of successful treatment of recalcitrant childhood localized scleroderma with infliximab and leflunomide","volume":"9","author":"Ferguson","year":"2015","journal-title":"Open Rheumatol J"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.semarthrit.2020.03.020","article-title":"Abatacept in the treatment of localized scleroderma: a pediatric case series and systematic literature review","volume":"50","author":"Kalampokis","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1093\/rheumatology\/keaa873","article-title":"Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma","volume":"60","author":"Li","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R43-20250526","first-page":"211","article-title":"Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?","volume":"35 Suppl 106","author":"Martini","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5301\/jsrd.5000259","article-title":"Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma patients","volume":"2","author":"Foeldvari","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/rheumatology\/kex382","article-title":"Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma","volume":"57","author":"Lythgoe","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jamadermatol.2018.5040","article-title":"A case of pansclerotic morphea treated with tocilizumab","volume":"155","author":"Zhang","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/2397198320975872","article-title":"Parry Romberg disease with En Coup de Sabre Scleroderma: effect of tocilizumab on periodontal bone inflammation","volume":"6","author":"Meneghetti","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"656407","DOI":"10.3389\/fimmu.2021.656407","article-title":"Case report: pansclerotic morphea-clinical features, differential diagnoses and modern treatment concepts","volume":"12","author":"Vent\u00e9jou","year":"2021","journal-title":"Front Immunol"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2340\/00015555-1136","article-title":"Abatacept is a promising treatment for patients with disseminated morphea profunda: presentation of two cases","volume":"91","author":"Stausb\u00f8l-Gr\u00f8n","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.semarthrit.2016.08.018","article-title":"Early- and late-stage morphea subtypes with deep tissue involvement is treatable with Abatacept (Orencia)","volume":"46","author":"Adeeb","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2340\/00015555-2878","article-title":"Abatacept improves skin-score and reduces lesions in patients with localized scleroderma: a case series","volume":"98","author":"Fage","year":"2018","journal-title":"Acta Derm Venereol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000886","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:16:42Z","timestamp":1748294202000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000886","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}